Entering text into the input field will update the search result below

Sorrento Therapeutics gets FDA greenlight for ESG-401 cancer trials

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • Sorrento Therapeutics (SRNE +1.5%) has received clearance from the U.S. FDA to proceed with clinical trials for the company's anti-TROP-2 antibody drug conjugate ESG-401.
  • The health regulator has given clearance to proceed with trials

Recommended For You

About SRNEQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SRNEQ--
Sorrento Therapeutics, Inc.